Since the incidence of the BRAF V600E mutation in NSCLC can reach up to 4% (16, 17), combining a meticulous pathologic assessment and ancillary techniques such as IHC would help the diagnosis (3, 13). This evidence concerns the gene BRAF and non-small cell lung carcinoma.